Loading…
Loading…
The notification inserts a new policy condition against the ITC-HS Chapter 29 entry covering ATS-8 (HS 2932.99), which previously carried a "Free" import policy with no specific condition. Any consignment with a declared CIF invoice value below USD 111/kg is reclassified to "Restricted," meaning the importer must obtain a DGFT Regional Authority licence before Customs clearance — a price-floor gate rather than a tariff or outright ban. Above-threshold imports continue to clear freely. The restriction runs from 18 September 2025 to 30 September 2026.
ATS-8 is the principal synthesis intermediate for Atorvastatin Calcium, the statin API used to treat elevated cholesterol and listed on India's National List of Essential Medicines. Global merchant-market ATS-8 production is concentrated among Chinese manufacturers. This notification is the earliest documented instance of a recurring DGFT pattern — a Chapter 29 CIF price floor rather than a formal DGTR anti-dumping investigation — subsequently applied to Sulfadiazine API (2025-10-10-india-dgft-mip-sulfadiazine-api, October 2025), potassium clavulanate (2025-12-18-india-dgft-mip-potassium-clavulanate, December 2025) and penicillin G/6-APA/amoxycillin (2026-01-29-india-dgft-mip-penicillin-6-apa-amoxycillin, January 2026). It sits alongside India's PLI Bulk Drugs scheme (2020-07-21-india-pli-bulk-drugs-ksm-di-api) as the import-protection half of a build-then-shield strategy for domestic API and intermediate capacity. Separately, Indian producer Arch Pharmalabs had already petitioned DGTR for a formal anti-dumping investigation into Chinese ATS-8 (File No. 6/11/2021-DGTR); that case is a distinct, unfiled instrument from this MIP notification and is not itself tracked in this register.
blanket import ban.
with India's pattern of using MIP as a reversible pressure tool rather than a permanent barrier.
formulation manufacturers' access to competitively priced imports.
quant), anchoring the measure to a specific price floor rather than a blanket restriction.
and downstream Atorvastatin producers gain a price floor against sub-threshold imports, mirroring the protection later extended to sulfadiazine, potassium-clavulanate and penicillin-family producers.
Lose access to the sub-threshold segment of the Indian market; above-floor exports remain permitted.
EOU/SEZ/AA exemptions, preserving cost-competitive sourcing for re-export Atorvastatin formulation production.
to a formal DGTR anti-dumping investigation, building on the dormant 2021 Arch Pharmalabs petition.
which specific manufacturers benefit (not disclosed in available sources).
data alongside China, given ATS-8 merchant supply is described elsewhere as China-concentrated — worth checking against India's Atorvastatin import statistics if a customs dataset becomes available.